HC Wainwright & Co. Maintains Buy on Akebia Therapeutics, Lowers Price Target to $4
Benzinga Newsdesk 2 days ago
Analyst RatingsNewsPrice Target
HC Wainwright & Co. analyst Matthew Caufield maintains Akebia Therapeutics (NASDAQ:AKBA) with a Buy and lowers the price target from $6 to $4.
HC Wainwright & Co. analyst Matthew Caufield maintains Akebia Therapeutics (NASDAQ:AKBA) with a Buy and lowers the price target from $6 to $4.